Only in Titles

Search results for: Mouse Anti-Human GRB2 Antibodies

paperclip

#12850474   // To Up

Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody.

Pancreatic cancer remains a devastating disease, with 95% of all patients diagnosed with the disease dying within 2 years. The combined therapy using Erbitux, gemcitabine, and radiation caused complete tumor regression using a nude mouse model inoculated with pancreatic MiaPaCa-2 cells but only a delay in tumor growth with BxPC-3. We investigated the effect of prolonged Erbitux treatment to the sensitivity to gemcitabine and/or radiation and the epidermal growth factor receptor (EGFR) signal transduction pathway.
Zhi-qiang Huang, Donald J Buchsbaum, Kevin P Raisch, James A Bonner, Kirby I Bland, Selwyn M Vickers

1543 related Products with: Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody.

100ug1 mg100ug Lyophilized0.1 mg1 module200 ug0.1 mg1.00 flask0.1 mg

Related Pathways